CBIO Q2 2023 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$265,866

Operating Income

-$9M

Net Income

-$8M

EPS (Diluted)

$-0.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$62M

Total Liabilities

$7M

Stockholders' Equity

$55M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$75,000	-100.0%
Gross Profit	-$265,866	$75,000	-454.5%
Operating Income	-$9M	-$13M	+33.1%
Net Income	-$8M	-$13M	+37.8%